SpyGlass Pharma Shares Eye Gains on Positive 4-Year Glaucoma Trial Data

Key Facts

1SpyGlass Pharma announced a 37% reduction in mean intraocular pressure across all dose groups in its clinical trials.

286% of patients remained off topical intraocular pressure-lowering drops 4 years after treatment with the BIM-IOL system.

SpyGlass Pharma announced a 37% reduction in mean intraocular pressure across all dose groups in its clinical trials for the BIM-IOL system. According to a statement released via GlobeNewswire, 86% of patients remained off topical intraocular pressure-lowering drops four years after treatment, highlighting the sustained efficacy of the company's long-acting drug delivery platform.

The company is developing this system to replace daily eye drops for glaucoma or ocular hypertension patients undergoing cataract surgery. SGP closed at $24.00 on October 16, 2026, having reached a day high of $24.84 and a low of $23.94 during that session.